These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 31493618

  • 1. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
    Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED.
    Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC.
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [Abstract] [Full Text] [Related]

  • 3. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP, Chan KH, Ng V, Tsui PT, You JHS.
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, Mowrey W, Billett HH.
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [Abstract] [Full Text] [Related]

  • 5. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ, San Agustin K, DeAngelo J, Campbell AM.
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI.
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI, Bunz TJ, Turpie AGG.
    Thromb Haemost; 2017 Oct 05; 117(10):1841-1847. PubMed ID: 28640322
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI, Yalçınkaya A, Hanedan MO, Erol ME, Ercen Diken Ö.
    Phlebology; 2018 Feb 05; 33(1):53-59. PubMed ID: 28056701
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI.
    Eur J Haematol; 2019 Feb 05; 102(2):143-149. PubMed ID: 30328143
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.
    Weaver P, Ng TH, Breeden T, Edwin SB, Haan B, ASCEND-HIGHER Research InitiativeDepartment of Pharmacy, Ascension Genesys Hospital, Grand Blanc, MI, USA.Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, USA.Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA., Giuliano C.
    Ann Pharmacother; 2022 Dec 05; 56(12):1315-1324. PubMed ID: 35505606
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI, Turpie AGG, Bunz TJ, Baker WL, Beyer-Westendorf J.
    Thromb Res; 2018 Mar 05; 163():132-137. PubMed ID: 29407625
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.
    J Thromb Thrombolysis; 2018 Oct 05; 46(3):339-345. PubMed ID: 29881958
    [Abstract] [Full Text] [Related]

  • 18. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S, Laliberté F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.
    Clin Ther; 2016 Aug 05; 38(8):1803-1816.e3. PubMed ID: 27491278
    [Abstract] [Full Text] [Related]

  • 19. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD, Rajpura J, Hlavacek P, Keshishian A, Sah J, Delinger R, Mu Q, Mardekian J, Russ C, Okano GJ, Rosenblatt L.
    J Manag Care Spec Pharm; 2020 Aug 05; 26(8):1017-1026. PubMed ID: 32452277
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.